New approach to diminish antibiotic resistance developed by research team from Freie Universität Berlin, the Hebrew University of Jerusalem, and ETH Zurich
Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at Charité – Universitätsmedizin Berlin and the German Center for Neurodegenerative Diseases…
Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery…
During the COVID-19 pandemic, Israel impressively demonstrated how efficient patient data collection can be used to advance research into the prevention of infections and development of therapies. One of Israel's largest healthcare organizations,…
Berlin researchers and their partners describe how aggressive variants of multiple myeloma can be detected early. Their comprehensive study in “Nature Cancer” shows how changes in genetic material affect the protein profile of the tumor cells, and…
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.
An open-source platform developed by researchers in Nikolaus Rajewsky’s lab at the Max Delbrück Center creates molecular maps from patient tissue samples with subcellular precision, enabling detailed study and potentially enhancing routine clinical…
Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the…
Berlin Center for Gene and Cell Therapies aspires to create a leading biotech ecosystem in Berlin / Federal Chancellor Scholz acknowledges the importance of the project for Germany / Governing Mayor of Berlin Kai Wegner assures support from the State…
Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa…
